ADVANCEMENTS IN DRUG DEVELOPMENT: SUSTAINABLE SYNTHETIC ROUTES AND MANUFACTURING

Ayush Kumar Soni[1], Piyush Yadav[2], Mohd. Wasiullah[3], Girijesh Yadav[4]

1. Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, U.P., India
2. Head, Department of Pharma: Chemistry, Prasad Institute of Technology Jaunpur, U.P., India
3. Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, U.P., India
4. Professor, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, U.P., India

Abstract

In order to lessen its impact on the environment, increase resource efficiency, and improve process safety while preserving product quality, the pharmaceutical sector is progressively implementing sustainable practices. The creation of environmentally safe synthetic pathways for active pharmaceutical ingredients (APIs) has been made possible by developments in green chemistry, catalysis, and process intensification. Waste, energy consumption, and solvent usage have been shown to be significantly reduced by techniques including step-economical and atom-efficient synthesis, one-pot processes, biocatalysis, solvent substitution, continuous manufacturing, and modular production systems. The adoption of sustainable techniques has been hastened by industry-led green chemistry programs, public-private collaborations, and regulatory guidelines from organizations like the FDA, EMA, and ICH. Technical, financial, scale-up, and regulatory obstacles still exist despite these developments. It is anticipated that new developments such as AI-driven route design, net-zero manufacturing, circular economy models, and the incorporation of sustainability in early drug discovery will further shift pharmaceutical development toward efficient and ecologically conscious production. This review critically evaluates existing techniques, industrial case studies, regulatory measures, and future perspectives in sustainable medication development, giving a comprehensive viewpoint for researchers, industry experts, and politicians.

Keywords: *Sustainable Drug Development, Green Chemistry, Pharmaceutical Manufacturing, Green Catalysis, Continuous Flow Synthesis, Solvent Replacement, Circular Economy, AI-Driven Process Optimization*

Corresponding Author

Ayush Kumar Soni, Research Scholar,
Prasad Institute of Technology, Jaunpur, U.P

Received: 09/02/2026
Revised: 19/02/2026
Accepted: 27/02/2026
DOI: http://doi.org/10.66204/GJPSR.316-2026-2-2-6

How to Cite

Soni AK, Yadav P, Wasiullah M, Yadav G. Advancements in drug development: sustainable synthetic routes and manufacturing. Global Journal of Pharmaceutical and Scientific Research. 2026;2(2):2–26. ISSN: 3108-0103. Doi: http://doi.org/10.66204/GJPSR.316-2026-2-2-6

1. Introduction

The pharmaceutical industry plays a critical role in global health through the development of life-saving medicines; however, it is also associated with considerable environmental impact due to energy-intensive processes, extensive solvent use, and significant chemical waste generation (Constable et al., 2007; Jiménez-González & Constable, 2011). Conventional batch-based drug manufacturing frequently needs many reaction and purification processes, resulting to inefficient resource use and huge environmental footprints. Increasing regulatory pressure, societal awareness, and business sustainability goals have thereby hastened the transition toward greener and more efficient pharmaceutical development processes (Dunn, 2012; Anastas & Zimmerman, 2018).

Green chemistry and green engineering, which prioritize waste reduction, atom economy, safer chemicals, and energy-efficient procedures, form the foundation of sustainable medication development (Anastas & Eghbali, 2010; Sheldon, 2017). It has been demonstrated that early application of these concepts during route design and process development greatly lowers solvent usage, dangerous byproducts, and total process mass. According to Jiménez-González et al. (2011) and Plutschack et al. (2017), sustainability measures like the E-factor, process mass intensity (PMI), and life cycle assessment (LCA) offer quantitative methods for assessing and enhancing environmental performance.

Environmentally friendly pharmaceutical production has been made possible by recent developments in catalysis, such as biocatalysis, organocatalysis, and photocatalysis, as well as continuous flow processing and process intensification (Clark et al., 2012; Mascia et al., 2013). In parallel, automation, digitalization, and AI-driven process optimization have boosted process control, scalability, and resource efficiency (Segler et al., 2018; Schweidtmann et al., 2021). Innovation and lifecycle-based sustainability approaches are still supported by industry-led green chemistry programs and regulatory frameworks from organizations like the FDA, EMA, and ICH.

This review summarizes recent advancements in sustainable drug development, focusing on green synthetic routes, enabling manufacturing technologies, regulatory drivers, and emerging trends, while highlighting current challenges and future opportunities for environmentally responsible pharmaceutical production.

2. Principles of Sustainable Drug Development

Sustainable drug development strives to balance therapeutic innovation with environmental protection, economic efficiency, and social responsibility. Conventional pharmaceutical

manufacture has a large environmental impact since it frequently involves multistep synthesis, intensive solvent usage, and high waste output. To address these difficulties, sustainability concepts are increasingly interwoven into drug discovery, process development, and commercial manufacturing, with green chemistry and green engineering serving as core frameworks (Anastas & Warner, 1998; Sheldon, 2017).

2.1 Concept of Green Chemistry and Green Engineering

The design of chemical processes that reduce or completely eradicate hazardous materials and waste production is the main goal of green chemistry. Atom efficiency, cleaner solvents and reagents, energy-efficient reactions, catalysis, and the use of renewable feedstocks are among the twelve tenets of green chemistry (Anastas & Warner, 1998). These guidelines direct early route selection in pharmaceutical development and promote the use of safer, more effective, and cleaner synthetic methods.

By addressing sustainability at the production and process levels, green engineering enhances this strategy. It emphasizes process intensification, lower energy usage, safer plant design, and integration of environmental factors throughout scale-up and commercialization (Anastas & Zimmerman, 2003). The combined application of green chemistry and green engineering enables the pharmaceutical sector to produce robust, scalable, and environmentally friendly manufacturing methods.

2.2 Sustainability Metrics in Pharmaceuticals (E-factor, PMI, Atom Economy)

Sustainability metrics are crucial instruments for evaluating pharmaceutical processes' environmental performance quantitatively. The Environmental factor (E-factor) illustrates the often high waste intensity of API manufacturing by calculating the amount of waste produced per unit of product (Sheldon, 2007). In the pharmaceutical business, Process Mass Intensity (PMI), which takes into consideration all material inputs such as water and solvents, has emerged as the preferred metric for evaluating alternative synthetic methods and promoting process optimization (Jiménez-González et al., 2011).

Atom economy, which is especially useful in the early stages of route design, assesses how well reactant atoms are integrated into the finished output. Although it does not consider solvent or energy use, atom economy supports practical measures such as PMI and E-factor, collectively promoting the development of greener and more material-efficient processes (Trost, 1991; Sheldon, 2017).

2.3 Regulatory and Ethical Drivers for Sustainable Manufacturing

Through frameworks like quality-by-design (QbD) and lifecycle management, which obliquely assist sustainable process development, regulatory bodies are increasingly promoting manufacturing innovation. Initiatives by the FDA, EMA, and ICH support flexible regulatory paths for sophisticated and continuous manufacturing technologies that can minimize waste and energy consumption (FDA, 2019).

Beyond regulation, ethical duties encourage the adoption of sustainable industrial techniques. Reducing environmental contamination, ensuring worker safety, and minimizing the ecological impact of pharmaceutical residues are critical societal obligations. Industry-led sustainability initiatives and green chemistry programs illustrate that environmentally responsible manufacturing can connect with economic success and long-term public health goals (Kümmerer, 2009; Constable et al., 2007).



Figure 1: Sustainable Drug Development Framework Across the Pharmaceutical Lifecycle

3. Sustainable Synthetic Routes in Drug Development

The design of sustainable synthetic pathways is crucial to decreasing the environmental footprint of pharmaceutical manufacture. Traditional medication production frequently includes lengthy multistep processes, significant solvent usage, and repetitive isolation and purification stages, all of which contribute to high material and energy consumption. Sustainable route development focuses on simplifying synthesis, improving efficiency, and integrating green chemistry principles early in process development to ensure scalability and regulatory compliance (Sheldon, 2017; Constable et al., 2007).

3.1 Route Selection and Process Intensification

The sustainability of medication manufacture is largely determined by route selection. Finding methods with fewer steps, safer chemicals, and higher yields is made possible by early examination of various synthetic pathways. Waste production and energy consumption are decreased by process intensification techniques including merging reaction and separation stages or boosting reaction efficiency with sophisticated reactors. Intensified processes have shown increased overall process robustness and lower PMI values in pharmaceutical production (Jiménez-González et al., 2011; Plutschack et al., 2017).

3.2 Atom-Efficient and Step-Economical Synthesis

The goal of atom-efficient synthesis is to minimize waste production by optimizing the incorporation of reactant atoms into the finished product. By reducing the number of synthetic transformations needed to obtain the target molecule, step economy further improves sustainability. Reactions such as catalytic couplings, cycloadditions, and rearrangements are favored due to their high atom usage and reduced demand for protective groups. Modern pharmaceutical route design is now guided by the combination of step economy and atom economy (Trost, 1991; Sheldon, 2017).

3.3 One-Pot and Multicomponent Reactions

Because they enable several bond-forming stages to take place in a single reaction vessel, one-pot and multicomponent reactions (MCRs) provide substantial sustainability benefits. These techniques eliminate intermediary isolation and purification, minimizing solvent use, processing time, and waste formation. MCRs are particularly interesting in drug development due to their high efficiency, structural variety, and compatibility with green solvents and catalysts, making them effective tools for both discovery and process development stages (Domling, Wang, & Wang, 2012).

3.4 Telescoped and Cascade Reactions

Telescoping involves completing consecutive reaction steps without isolating intermediates, while cascade reactions permit sequential transformations induced by a single reaction event. Both approaches cut down on production time, work-up procedures, and solvent consumption. In pharmaceutical manufacturing, telescoped processes have been successfully applied at scale, resulting to better safety and reduced environmental impact. Additionally, these methods promote continuous production integration and improve process control (Anderson, 2012; Plutschack et al., 2017).

3.5 Solvent-Free and Aqueous-Phase Synthesis

Solvents account for a large amount of waste in pharmaceutical processes, making solvent reduction and replacement essential sustainability priorities. Mechanochemical methods and other solvent-free syntheses completely eliminate solvent waste and frequently increase reaction rates and selectivity. When paired with catalysis or biocatalysis, aqueous-phase synthesis provides a safer and more environmentally friendly substitute for conventional organic solvents. A larger trend in drug development toward more environmentally friendly synthetic approaches is shown in the growing use of water and solvent-free systems (Li & Trost, 2008; James et al., 2012).

Table 1: Sustainable Synthetic Strategies for Pharmaceutical APIs

Strategy	Key Features	Advantages
Atom-Efficient & Step-Economical Synthesis	Minimizes number of steps, maximizes incorporation of reactants into product	Reduces waste, lowers energy use, improves yield
One-Pot & Multicomponent Reactions	Multiple transformations in a single vessel	Reduces purification steps, solvent usage, and reaction time
Telescoped & Cascade Reactions	Sequential reactions without isolation of intermediates	Minimizes intermediate handling, solvent, and energy
Biocatalysis / Enzyme-Mediated Reactions	Use of enzymes for specific transformations	High selectivity, mild conditions, biodegradable catalysts
Green Catalysis (Metal / Organocatalysis / Photocatalysis)	Catalysts enable efficient transformations under milder conditions	Reduced energy input, improved reaction efficiency, catalyst reusability
Solvent-Free / Aqueous-Phase Synthesis	Reactions in water or without solvent	Minimizes hazardous solvent usage, safer conditions

4. Green Catalysis in Pharmaceutical Synthesis

Catalysis is a cornerstone of sustainable pharmaceutical synthesis, enabling efficient chemical reactions while considerably lowering waste, energy consumption, and environmental effect. Compared with stoichiometric reactions, catalytic methods enhance atom usage, improve selectivity, and decrease the formation of undesirable by-products. The strategic use of green catalytic systems has become crucial for attaining sustainable, scalable, and financially feasible pharmaceutical manufacturing as current medicine compounds get more complicated (Sheldon, 2017; Sheldon & Woodley, 2018).

To address sustainability issues throughout the research and development phases, the pharmaceutical industry has embraced a broad range of catalytic methodologies, such as metal catalysis, organocatalysis, biocatalysis, and newly developed photocatalytic and electrocatalytic techniques. These approaches not only facilitate greener synthesis but also align with regulatory standards relating to product quality, impurity control, and process resilience.

4.1 Metal Catalysis and Catalyst Recovery

By facilitating extremely effective bond-forming processes including hydrogenations, selective oxidations, and carbon–carbon and carbon–heteroatom couplings, transition metal catalysis has transformed medicinal synthesis. Palladium-, nickel-, ruthenium-, and copper-catalyzed processes are frequently exploited in the synthesis of active pharmaceutical ingredients (APIs) due to their high yields, broad substrate scope, and strong functional group tolerance. These catalytic techniques frequently take the role of multi-step stoichiometric procedures, increasing atom economy and lowering waste production.

Despite these benefits, careful catalyst selection and recovery techniques are required due to issues with metal toxicity, scarcity, expense, and residual metal impurities. The development of heterogeneous catalysts, immobilized metal systems, and recyclable catalyst supports is fueled by regulatory bodies' stringent restrictions on elemental impurities in pharmaceutical products. Technological developments in catalyst separation, such as membrane-based recovery, adsorption, and filtration, have made it possible to reuse catalysts effectively while maintaining regulatory compliance. The sustainability and economic viability of metal-catalyzed pharmaceutical processes are greatly improved by these advancements (de Vries & Elsevier, 2007; Sheldon, 2017).

4.2 Organocatalysis in Drug Synthesis

Organocatalysis has developed as a powerful and environmentally friendly alternative to metal-based catalysis, notably for asymmetric synthesis. Under mild circumstances, a variety of enantioselective transformations are catalyzed by small chemical molecules, including amino acids, thiourea derivatives, and chiral amines. The metal-free characteristic of organocatalysis reduces problems associated to metal contamination and simplifies downstream purification, making it particularly desirable for pharmaceutical applications.

In addition to its environmental benefits, organocatalysis offers operational simplicity, compatibility with aqueous or green solvents, and great stereochemical control. Its use in the production of chiral drug intermediates and APIs has been made easier by these

characteristics. Their importance in sustainable medication manufacture is further strengthened by the ongoing discovery of highly active and recyclable organocatalysts (List, 2007; MacMillan, 2008).

4.3 Biocatalysis and Enzyme-Mediated Reactions

Using enzymes to carry out extremely selective chemical changes, biocatalysis is one of the most environmentally friendly methods of pharmaceutical production. Enzymes usually function in mild environments, such as ambient temperature, air pressure, and aqueous fluids, and they have remarkable chemo-, regio-, and enantioselectivity. When compared to traditional chemical techniques, these characteristics lead to lower energy usage, less waste production, and increased safety.

The use of biocatalysis in drug development has been greatly increased by recent developments in directed evolution, protein engineering, and enzyme immobilization. Enzymes are now commonly utilized for asymmetric reductions, oxidations, hydrolyses, and carbon–carbon bond-forming processes in industrial API synthesis. As a result, biocatalytic processes often demonstrate superior sustainability metrics, including lower PMI and E-factor values, reinforcing their growing importance in green pharmaceutical manufacturing (Bornscheuer et al., 2012; Sheldon & Woodley, 2018).

4.4 Photocatalysis and Electrocatalysis

Emerging catalytic technologies like photocatalysis and electrocatalysis use sustainable energy sources like light and electricity to propel chemical reactions. Photocatalytic processes, particularly visible-light photoredox catalysis, provide novel reaction pathways using single-electron transfer mechanisms, generally under mild and ecologically favorable conditions. These approaches lessen dependency on toxic oxidants and reductants, contributing to safer and cleaner synthesis.

Similar benefits are provided by electrocatalysis, which promotes redox processes by substituting electrical energy for chemical reagents. Electrocatalytic methods for selective oxidations, reductions, and carbon-carbon bond formation have been investigated in pharmaceutical production. While challenges related to scalability, equipment cost, and process integration persist, ongoing technological advancements are steadily improving the industrial feasibility of these methods, positioning them as promising tools for sustainable drug manufacturing (Prier et al., 2013; Yan et al., 2017).

4.5 Sustainable Catalyst Design and Reusability

The goal of sustainable catalyst design is to create systems with minimal environmental impact and high catalytic performance. The utilization of earth-abundant metals, renewable or biodegradable catalyst components, and sturdy catalyst supports that allow for long-term reuse are important tactics. Catalyst stability and recyclability are particularly significant in pharmaceutical manufacture, where large-scale operations necessitate consistent performance over extended operational cycles.

Integrating sustainability factors into catalyst development decreases material consumption, lowers operational costs, and boosts overall process efficiency. As pharmaceutical manufacturing develops toward continuous processing and digitalized production platforms, robust and reusable catalysts will play an increasingly crucial role in allowing greener, more resilient drug manufacturing systems (Anastas & Zimmerman, 2003; Sheldon, 2017).

5. Sustainable Solvents and Reaction Media

The majority of waste, environmental effects, and safety hazards related to drug synthesis are caused by solvents, which make up the greatest material input in pharmaceutical manufacturing. Solvent selection is crucial to sustainable drug development because conventional organic solvents are frequently flammable, poisonous, volatile, and produced from nonrenewable resources. As a result, replacing toxic solvents with safer and more ecologically benign alternatives has become a significant focus of green chemistry activities within the pharmaceutical sector (Constable et al., 2007; Sheldon, 2017).

Sustainable solvent methods focus on eliminating solvents, replacing them with more environmentally friendly options, recycling solvents, and creating innovative reaction media that lower occupational and environmental risks while preserving reaction efficiency and product quality.

5.1 Replacement of Hazardous Organic Solvents

Due to their toxicity, persistence, and high volatility, many widely used pharmaceutical solvents, including dichloromethane, chloroform, N,N-dimethylformamide (DMF), and N-methyl-2-pyrrolidone (NMP), present serious risks to the environment and human health. Efforts to replace these solvents with safer substitutes that have less toxicity, less of an impact on the environment, and better biodegradability have been motivated by regulatory pressure and sustainability objectives.

Solvent selection guides and solvent sustainability assessment tools established by pharmaceutical firms and consortia give practical frameworks for choosing greener solvents based on safety, environmental, and lifecycle factors. Pharmaceutical manufacturing has

shown less waste production, increased process safety, and improved regulatory compliance when hazardous solvents are replaced with alcohols, esters, ethers, and water-compatible systems (Capello et al., 2007; Alder et al., 2016).

5.2 Bio-Based and Renewable Solvents

Bio-based and renewable solvents derived from biomass provide an important class of sustainable alternatives to petroleum-based solvents. Terpenes, glycerol derivatives, 2-methyltetrahydrofuran (2-MeTHF), ethanol, and ethyl lactate are a few examples. These solvents often display favorable environmental profiles, including renewability, decreased toxicity, and better biodegradability.

In pharmaceutical synthesis, bio-based solvents have been successfully employed in extraction, crystallization, and reaction procedures, typically delivering equivalent or greater performance to standard solvents. The use of renewable solvents also contributes to reduced carbon footprint and supports circular economy concepts, making them attractive solutions for sustainable medicine manufacture (Clark et al., 2012; Gu & Jérôme, 2013).

5.3 Supercritical Fluids and Ionic Liquids

Supercritical fluids, particularly supercritical carbon dioxide ($scCO_2$), have received interest as green reaction and processing media due to their tunable physicochemical features, non-toxicity, and ease of separation. In pharmaceutical applications, such as particle creation, extraction, and some catalytic activities, $scCO_2$ has been used to provide solvent-free product recovery and minimize waste production.

Ionic liquids, made solely of ions, display minimal vapor pressure, great thermal stability, and variable solvation properties. They are appealing substitutes for volatile organic solvents because of these qualities. However, their widespread acceptance has been constrained by issues with cost, toxicity, and environmental permanence. To improve their sustainability profile in pharmaceutical processes, ongoing research focuses on creating task-specific and biodegradable ionic liquids (Jessop, Leitner, & Beckman, 2012; Plechkova & Seddon, 2008).

5.4 Deep Eutectic Solvents (DES)

Because of their low toxicity, ease of manufacture, and biodegradability, deep eutectic solvents (DES) have become a viable green solvent system. DES, which are often created by combining hydrogen bond donors and acceptors, have physicochemical characteristics that are comparable to ionic liquids but are more affordable and environmentally friendly.

In pharmaceutical synthesis, DES have showed utility as reaction media, extraction solvents, and catalytic systems, particularly for biocatalytic and metal-catalyzed processes. DES are

adaptable and sustainable substitutes for pharmaceutical manufacturing due to their tunable qualities and compatibility with renewable components (Abbott et al., 2003; Smith, Abbott, & Ryder, 2014).

5.5 Water as a Green Reaction Medium

Water is commonly regarded as the ultimate green solvent due to its abundance, non-toxicity, non-flammability, and low cost. Significant developments have made it possible to employ water as a reaction medium for a variety of organic transformations, despite earlier difficulties with solubility and reaction compatibility. Catalysis, surfactant-mediated systems, and biocatalytic methods have broadened the utility of aqueous-phase synthesis in pharmaceutical development.

Water-based reactions frequently show higher reaction rates, better selectivity, and easier product isolation. A fundamental change toward pharmaceutical production that is intrinsically safer and more sustainable is reflected in the growing usage of aqueous and water-based technologies (Li & Trost, 2008; Sheldon, 2017).

6. Advances in Pharmaceutical Manufacturing Technologies

By increasing process efficiency, cutting waste, improving product quality, and boosting operational flexibility, technological innovation in pharmaceutical production has emerged as a major enabler of sustainability. Conventional batch manufacturing is frequently associated with high solvent use, extended processing durations, and poor process control. Modern manufacturing technologies, on the other hand, combine digital tools, real-time monitoring, and sophisticated process design to enable more resilient and environmentally friendly drug manufacture. These developments are in line with regulatory efforts that support innovation while preserving patient safety and product quality (FDA, 2019; ICH Q8–Q10).

6.1 Continuous Flow Manufacturing

A revolutionary strategy for environmentally friendly pharmaceutical production is continuous flow manufacturing. Continuous manufacturing, as opposed to batch processes, allows for continuous material flow through reactors and unit activities, which improves mass and heat transfer, reaction control, and footprint. These characteristics support constant product quality, enhanced safety, and reduced energy usage.

Continuous flow systems have been effectively used in pharmaceutical synthesis for formulation, crystallization, and API synthesis. By prolonging operation time instead of expanding reactor space, continuous production also enables process intensification, decreased solvent consumption, and simpler scale-up. Continuous manufacturing has gained

more support from regulatory bodies as a way to improve sustainability and quality across the product lifetime (Plutschack et al., 2017; FDA, 2019).

6.2 Process Analytical Technology (PAT) and Quality by Design (QbD)

Process Analytical Technology (PAT) and Quality by Design (QbD) are regulatory-driven frameworks that enable systematic understanding and control of pharmaceutical processes. PAT uses sophisticated analytical techniques to monitor important process parameters and quality features in real-time, allowing for the quick identification and rectification of process abnormalities. This real-time control decreases batch failures, reprocessing, and material waste.

QbD supports PAT by stressing predefined quality targets, risk assessment, and design space development during process design. Together, PAT and QbD promote robust and reproducible production processes, reduce variability, and enhance resource efficiency. Their integration into sustainable manufacturing strategies has shown beneficial in lowering waste, optimizing energy use, and enhancing overall process reliability (Rathore & Winkle, 2009; ICH Q8–Q10).

6.3 Automation and Digitalization in Sustainable Manufacturing

Automation and digitalization have become crucial to sustainable pharmaceutical manufacturing by enabling precise process control, data-driven decision-making, and reduced human error. Automated systems increase worker safety, maximize resource usage, and improve reproducibility. Digital tools such as sophisticated sensors, machine learning algorithms, and digital twins offer real-time process optimization and predictive maintenance. By lowering downtime, cutting down on raw material losses, and increasing energy efficiency, the integration of digital manufacturing platforms promotes sustainability. Moreover, digitalization facilitates compliance with regulatory standards through better data integrity and traceability. Digital transformation is anticipated to reinforce sustainable practices in pharmaceutical manufacturing as Industry 4.0 concepts gain momentum (Lee et al., 2015; Gernaey et al., 2020).

6.4 Modular and Flexible Manufacturing Systems

A flexible approach to pharmaceutical production is provided by modular and flexible manufacturing systems, which allow for quick reaction to supply chain interruptions, product variations, and market needs. Modular units can be modified or scaled independently, lowering capital expenditure and energy consumption compared to big stationary plants. From a sustainability standpoint, modular manufacturing lowers transportation-related

emissions by enabling localized production and reducing waste from process switches. Flexible methods are particularly helpful for creating small-volume, high-value medications and tailored therapies. Modular manufacturing is anticipated to be crucial in facilitating resilient and sustainable medication supply chains as the pharmaceutical industry moves toward more flexible and decentralized production models (Rogers & Ierapetritou, 2015; Mascia et al., 2013).

7. Waste Minimization and Resource Efficiency

The main goals of sustainable pharmaceutical manufacture are waste reduction and effective resource use. The manufacturing of active pharmaceutical ingredients (APIs) is generally characterized by high material input, substantial solvent use, and energy-intensive activities, resulting in large waste streams. Increasing resource efficiency decreases production costs, improves process robustness, and lessens the impact on the environment. Consequently, pharmaceutical manufacturers increasingly prioritize waste reduction methods across the whole drug research and manufacturing lifecycle (Sheldon, 2007; Jiménez-González & Constable, 2011).

7.1 Waste Reduction Strategies in API Manufacturing

Waste reduction in API manufacturing begins with strategic route design and process optimization. Simplifying synthetic pathways, lowering the number of reaction and purification stages, and boosting reaction selectivity are useful approaches to minimizing waste formation. The introduction of catalytic procedures in place of stoichiometric reactions considerably reduces reagent consumption and by-product production. Additionally, deleting protective groups and adopting telescoped or one-pot methods significantly minimizes solvent use and solid waste formation.

Advanced manufacturing methods, such as continuous flow processing and process intensification, also help to waste reduction by boosting reaction efficiency and eliminating off-spec material. Implementation of green chemistry metrics, including E-factor and PMI, enables quantitative assessment of waste reduction initiatives and leads continuous process improvement in pharmaceutical manufacturing (Sheldon, 2007; Plutschack et al., 2017).

7.2 Recycling and Reuse of Solvents and Reagents

Solvents often account for the biggest share of material utilization and waste in pharmaceutical procedures. Thus, recycling and reusing chemicals and solvents are very successful ways to increase sustainability. Distillation, membrane separation, and adsorption

processes are routinely applied to recover and purify solvents for reuse without affecting product quality.

In addition to solvent recovery, catalyst and reagent recycling has attracted growing interest, particularly in large-scale API manufacturing. Reuse of catalysts and reagents minimizes raw material consumption, lowers waste disposal requirements, and improves economic performance. PMI and total environmental impact have been shown to significantly decrease when solvent and reagent recycling is incorporated into production workflows (Constable et al., 2007; Alder et al., 2016).

7.3 Energy-Efficient Processes

The environmental impact of pharmaceutical manufacture is significantly influenced by energy use, especially during the heating, cooling, and separation processes. The goal of energy-efficient process design is to lower energy consumption by using alternative technologies like continuous processing and microwave-assisted synthesis, better heat integration, and optimal reaction conditions.

Process intensification and automation enable precise control of temperature, pressure, and residence time, resulting in lower energy usage and improved reproducibility. Additionally, shifting from batch to continuous manufacturing frequently leads to reduced energy use per unit of product. These solutions help both environmental sustainability and cost savings in pharmaceutical operations (Rogers & Ierapetritou, 2015; Sheldon, 2017).

7.4 Life Cycle Assessment (LCA) in Drug Manufacturing

Life Cycle Assessment (LCA) is a thorough analytical tool used to evaluate the environmental impact of pharmaceutical products across their full lifecycle, from raw material extraction to production, distribution, use, and disposal. LCA makes it possible to compare different manufacturing routes, identify environmental hotspots, and help well-informed decision-making during process development.

LCA is being used more often in pharmaceutical manufacture to evaluate the sustainability of manufacturing technology, solvent choices, and synthesis pathways. The creation of more sustainable pharmaceutical products is aided by the integration of LCA with green chemistry metrics, which offers a comprehensive assessment of environmental performance. As sustainability reporting becomes more popular, LCA is likely to play a significant role in guiding ecologically responsible pharmaceutical manufacture (ISO 14040; Jiménez-González et al., 2011).

Table 2: Comparative Analysis of Conventional vs. Sustainable Pharmaceutical Manufacturing

Aspect	Conventional Manufacturing	Sustainable Manufacturing	Benefits / Notes
Process Type	Batch-based	Continuous / Flow-based	Improved control, reproducibility, reduced energy
Solvent Use	Large volumes, often hazardous	Green solvents, aqueous or bio-based	Reduced environmental impact, safer handling
Catalysis	Stoichiometric reagents or non-recoverable catalysts	Metal, organo, and biocatalysis	Reduced waste, higher selectivity
Energy Consumption	High due to heating/cooling and multi-step operations	Energy-efficient processes, process intensification	Lower carbon footprint, reduced costs
Waste Generation	High E-factor, extensive purification	Low E-factor, step-economical synthesis	Less chemical waste, easier regulatory compliance
Scalability & Flexibility	Limited by batch equipment	Modular, flexible, easily scalable	Faster response to demand, consistent quality
Regulatory Considerations	Well-established but less sustainability focus	Requires validation for new processes	Aligns with QbD, PAT, and environmental guidance

8. Case Studies of Sustainable Drug Development

Case studies provide real examples of how sustainability principles can be successfully integrated into pharmaceutical medication research and manufacture. Although the principles of green chemistry are well-established, their implementation in industrial processes necessitates careful consideration of cost, safety, efficiency, and regulatory compliance. Sustainable methods can greatly lessen environmental effect while enhancing process robustness and economic performance, as some pharmaceutical businesses have shown. These case studies show the concrete benefits of sustainable synthetic methods and production strategies.

8.1 Green Synthesis of Small-Molecule APIs

Redesigning synthetic pathways can result in significant sustainability improvements in the manufacturing of small-molecule APIs, as demonstrated by numerous cases. Green synthesis techniques frequently focus on lowering the number of reaction steps, substituting hazardous chemicals, enhancing atom economy, and minimizing solvent usage. For example, conventional stoichiometric chiral resolution techniques have been superseded by catalytic asymmetric hydrogenation and biocatalytic transformations, leading to increased yields, decreased waste, and enhanced enantioselectivity. In some recorded examples, route redesign has led to large reductions in E-factor and PMI values, primarily by eliminating protective groups and telescoping multiple steps. The inclusion of aqueous and bio-based solvents, together with continuous flow technology, has further boosted sustainability outcomes. According to Sheldon (2017) and Jiménez-González et al. (2011), these examples show how early incorporation of green chemistry principles during route selection can result in long-term environmental and economic benefits throughout the product lifecycle.

8.2 Industrial Case Studies from Major Pharmaceutical Companies

Sustainability-driven advances in API manufacturing have been actively adopted by major pharmaceutical corporations. By redesigning synthetic routes using greener solvents and catalytic procedures, Pfizer achieved considerable savings in waste and solvent use. In a similar vein, Merck achieved lower PMI values and increased process efficiency by effectively implementing biocatalysis and step-economical synthesis to enhance the sustainability of several API production processes.

Leading the way in solvent sustainability, GlaxoSmithKline (GSK) has created industry-wide solvent selection guidelines. Using these guidelines has made it possible to use safer solvents, lower environmental risks, and enhance regulatory compliance. Additionally, AstraZeneca and Novartis have included life cycle assessment (LCA) tools and green chemistry indicators into decision-making processes, ensuring sustainability considerations are embedded throughout drug development. Sustainability initiatives can be in line with company goals and regulatory requirements, as these industry examples show (Constable et al., 2007; Alder et al., 2016).

8.3 Comparison of Conventional vs. Sustainable Routes

The benefits of green drug development strategies are highlighted by comparisons between conventional and sustainable synthetic pathways. Conventional methods frequently result in substantial waste generation and environmental load due to multistep batch processes, hazardous reagents, heavy solvent use, and energy-intensive operations. In contrast,

sustainable routes emphasize catalytic reactions, solvent reduction or replacement, process intensification, and continuous manufacturing.Reductions in waste, energy consumption, and processing time for sustainable procedures are routinely reported in studies comparing alternative pathways. Improved safety profiles, more scalability, and lower E-factor and PMI values are frequently noted results. The case for broad adoption of green manufacturing practices in the pharmaceutical industry is strengthened by these comparisons, which highlight the significance of incorporating sustainability metrics and lifecycle thinking into route selection and process development (Sheldon, 2007; Jiménez-González & Constable, 2011).



Figure 2: Comparison of Conventional and Sustainable Pharmaceutical Manufacturing Routes

9. Role of Regulatory Agencies and Industry Initiatives

Regulatory bodies and industry-led initiatives play a vital role in advancing sustainable drug development by creating rules, rewarding innovation, and fostering collaboration across the pharmaceutical value chain. Regulations increasingly promote the use of green chemistry, energy-efficient manufacturing, and lifecycle-based decision-making, even though sustainability is not often expressly required. At the same time, public-private partnerships and industrial consortiums have become significant forces behind innovation focused on sustainability.

9.1 Guidelines from FDA, EMA, and ICH

Global regulatory organizations including the International Council for Harmonization (ICH), the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA) have gradually included sustainability-related concepts into pharmaceutical development and manufacturing guidelines. The FDA advocates modern manufacturing practices, like

continuous manufacturing, Quality by Design (QbD), and Process Analytical Technology (PAT), which intrinsically support waste minimization, increased resource efficiency, and reduced environmental impact.

Similar to this, the EMA's guidelines on pharmaceutical quality and environmental protection promote lifecycle management, environmental risk assessment (ERA), and more environmentally friendly production techniques. The ICH guidelines—particularly ICH Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System)—provide a harmonized framework that allows the development of robust, efficient, and sustainable manufacturing processes. These standards' emphasis on process understanding, control, and continuous improvement is in accordance with sustainability goals even though they do not specifically require green chemistry (FDA, 2019; EMA, 2023; ICH, 2009).

9.2 Industry-Led Green Chemistry Programs

The adoption of sustainable practices in drug development has accelerated thanks to industry-led initiatives that go beyond regulatory frameworks. One well-known example is the ACS Green Chemistry Institute® Pharmaceutical Roundtable (GCIPR), which brings together significant pharmaceutical companies to determine research objectives, exchange best practices, and create tools that facilitate the production of greener APIs. The roundtable has advanced sustainable catalysis, greener reagents, and solvent selection.

Additionally, a number of pharmaceutical businesses have put in place internal sustainability initiatives aimed at cutting waste production, solvent use, and carbon emissions. Route selection and process development are increasingly using industry-developed solvent selection guides, green metrics dashboards, and sustainability scorecards. These voluntary activities illustrate that sustainability may be integrated into core company objectives without compromising product quality or regulatory compliance (Lipshutz et al., 2018; Roschangar et al., 2015).

9.3 Public–Private Partnerships for Sustainable Pharma

By fusing regulatory knowledge, intellectual creativity, and business know-how, public-private partnerships (PPPs) have become powerful platforms for promoting sustainable pharmaceutical manufacture. Collaborative projects such as the Innovative Medicines Initiative (IMI) in Europe and the U.S. National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) assist the development of innovative, sustainable manufacturing methods.

These collaborations make it possible to invest together in high-risk research fields including digitalization, continuous production, and more environmentally friendly synthetic techniques. PPPs assist in lowering adoption barriers and facilitating regulatory approval of innovative, sustainable technology by encouraging information exchange and standardization. As sustainability concerns grow more complex, such collaborative approaches are projected to play an increasingly crucial role in shaping the future of environmentally responsible medication development (IMI, 2021; NIIMBL, 2022).

10. Challenges and Limitations

The broad use of green synthetic methods and manufacturing technology is still constrained by a number of issues, despite notable advancements in sustainable medicine creation. These issues cover technical feasibility, economic limits, scale-up problems, and regulatory concerns. Addressing these limitations is essential for translating laboratory-scale innovations into robust, industrially viable pharmaceutical processes.

10.1 Technical and Economic Barriers

The technological constraints related to reaction efficiency, selectivity, and robustness are among the main obstacles in putting sustainable synthetic techniques into practice. Green substitutes including biocatalysis, solvent-free reactions, and innovative catalytic systems might have smaller operating windows, a smaller range of substrates, or be more sensitive to changes in the process. Furthermore, the wider use of enzymes, catalysts, and renewable raw materials may be restricted by their availability and long-term stability.

Economic concerns also play a vital part in decision-making throughout process development. The initial expenditures of process redesign, catalyst development, and equipment modification might be high, even though sustainable pathways frequently result in lower waste and energy consumption. For legacy items, the economic motivation to replace an already verified and approved production technique may be restricted, particularly when short product life cycles or low profit margins are involved. Consequently, sustainability programs must exhibit obvious cost–benefit advantages to attain widespread industrial adoption (Anastas & Zimmerman, 2018; Dunn, 2012).

10.2 Scale-Up and Industrial Implementation Issues

It is still very difficult to scale up sustainable synthetic technologies from lab or pilot scale to commercial manufacturing. Reaction conditions that function efficiently at small scale may behave unpredictably at greater volumes due to heat transfer limits, mass transport problems, or catalyst deactivation. Even though continuous flow and intensified processes provide

sustainability benefits, they frequently call for specialized tools and knowledge that might not be easily accessible at every manufacturing location.

It can also be difficult and resource-intensive to integrate new technologies into the current production infrastructure. Compatibility with downstream processing, solvent recovery systems, and waste treatment facilities must be carefully considered. In order to guarantee that sustainability-driven innovations are both industrially viable and scalable, these scale-up problems underscore the significance of early collaboration between chemists, engineers, and production teams (Plutschack et al., 2017; Kralisch & Ott, 2011).

10.3 Regulatory and Validation Challenges

Implementing sustainable manufacturing solutions is further complicated by regulatory obligations. Any major modification to the synthetic pathway, raw materials, or processing conditions usually necessitates thorough validation and regulatory permission, which can be expensive and time-consuming. This is particularly hard for post-approval adjustments to established products, as regulatory uncertainty may inhibit the adoption of greener alternatives.

Furthermore, the absence of clear regulatory incentives or uniform sustainability measures in regulatory frameworks may reduce the incentive for change. While current rules stimulate innovation and process understanding, they do not compel sustainable objectives, leaving implementation mostly optional. While preserving product quality and patient safety, more regulatory harmonization, clarity, and acknowledgment of sustainability benefits should hasten the adoption of greener drug development techniques (Woodcock & Woosley, 2008; Schuhmacher et al., 2020).

11. Future Perspectives and Emerging Trends

The future of medication development is increasingly driven by the combination of digital technology, sustainability science, and altering regulatory expectations. As environmental impact, supply chain resilience, and resource efficiency become strategic concerns, pharmaceutical businesses are moving beyond incremental gains toward revolutionary, sustainability-driven innovation. It is anticipated that new developments like net-zero manufacturing, early-stage sustainability integration, artificial intelligence-enabled process design, and circular economy models will completely change the way medications are found, created, and manufactured.

11.1 AI-Driven Route Design and Process Optimization

Pharmaceutical development's synthetic route design and process optimization are being quickly transformed by artificial intelligence (AI) and machine learning (ML). Advanced algorithms can examine enormous reaction datasets to anticipate optimal synthetic pathways, suggest greener alternatives, and limit waste output. Chemists can choose paths that strike a balance between performance and environmental concerns thanks to AI-driven retrosynthetic planning tools that increasingly include sustainability indicators like energy efficiency, solvent effect, and atom economy.

In manufacturing, AI-based process control and digital twins offer real-time optimization of reaction conditions, energy utilization, and material consumption. These tools promote continuous improvement, lessen trial-and-error experimentation, and improve process robustness. As data availability and model interpretability improve, AI is projected to play a major role in accelerating sustainable innovation across the pharmaceutical lifecycle (Segler et al., 2018; Schweidtmann et al., 2021).

11.2 Integration of Sustainability in Early Drug Discovery

Integrating sustainability considerations at the earliest stages of drug discovery represents a paradigm shift from traditional, late-stage process optimization. Early evaluation of synthetic feasibility, solvent selection, and scalability can prevent the development of environmentally burdensome routes that are difficult to redesign later. Increasingly, medicinal chemists are adopting green chemistry principles during lead optimization to ensure that promising drug candidates are compatible with sustainable manufacturing.

The application of predictive tools and sustainability scorecards during discovery enables informed decision-making before large resources are committed. This proactive approach not only decreases downstream environmental effect but also shortens development timetables and lowers overall costs. Thus, incorporating sustainability into early drug discovery is becoming a crucial tactic for attaining long-term economic and environmental advantages (Blakemore et al., 2018; Sherwood et al., 2019).

11.3 Net-Zero and Carbon-Neutral Pharmaceutical Manufacturing

Achieving net-zero and carbon-neutral pharmaceutical manufacturing has become a strategic goal for several worldwide pharmaceutical corporations. Energy-efficient procedures, electrification of manufacturing processes, increased use of renewable energy, and supply chain optimization are the main strategies used to lower greenhouse gas emissions. Process intensification, continuous manufacturing, and reduced solvent usage directly contribute to lower carbon footprints.

In addition, lifecycle-based carbon accounting and science-based targets are increasingly being implemented to guide decarbonization initiatives. It is anticipated that developments in energy management, digitalization, and green process design will hasten the transition to carbon-neutral pharmaceutical production, even though reaching net-zero manufacturing poses substantial technical and logistical challenges (Belkhir & Elmeligi, 2019; McDonough et al., 2021).

11.4 Circular Economy Approaches in Pharma

Adopting the concepts of the circular economy offers a revolutionary chance for sustainable pharmaceutical development. Throughout the medication manufacturing lifecycle, circular approaches prioritize waste prevention, material reuse, solvent recycling, and by-product valuation. Advanced solvent recovery systems, closed-loop production, and reuse of catalysts and reagents are progressively being adopted to limit resource usage.

Beyond manufacturing, circular strategies extend to packaging, supply chain management, and end-of-life considerations for pharmaceuticals. Collaboration across industry, regulators, and academia is essential to establish standardized frameworks and infrastructure that support circularity. As regulatory and societal pressures intensify, circular economy models are expected to play a critical role in shaping the future of sustainable pharmaceutical manufacturing (Geissdoerfer et al., 2017; Stahel, 2016).

12. Acknowledgements

The authors would like to express their sincere gratitude to all the researchers and institutions whose work has contributed to the development of this review.

13. Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this review.

14. Conclusion

- Alder, C. M., Hayler, J. D., Henderson, R. K., Redman, A. M., Shukla, L., Shuster, L. E., & Sneddon, H. F. (2016). Updating and further expanding GSK's solvent sustainability guide. *Green Chemistry, 18*(13), 3879–3890. https://doi.org/10.1039/C6GC00611F
- Anastas, P. T., & Eghbali, N. (2010). Green chemistry: Principles and practice. *Chemical Society Reviews, 39*(1), 301–312. https://doi.org/10.1039/B918763B

- Anastas, P. T., & Zimmerman, J. B. (2018). The periodic table of the elements of green and sustainable chemistry. *Green Chemistry, 20*(9), 1929–1961. https://doi.org/10.1039/C8GC00559B
- Belkhir, L., & Elmeligi, A. (2019). Carbon footprint of the global pharmaceutical industry and relative impact of its major players. *Journal of Cleaner Production, 214*, 185–194. https://doi.org/10.1016/j.jclepro.2018.11.204
- Blakemore, D. C., Castro, L., Churcher, I., Rees, D. C., Thomas, A. W., Wilson, D. M., & Wood, A. (2018). Organic synthesis provides opportunities to transform drug discovery. *Nature Chemistry, 10*(4), 383–394. https://doi.org/10.1038/s41557-018-0021-z
- Clark, J. H., Farmer, T. J., Hunt, A. J., & Sherwood, J. (2012). Opportunities for bio-based solvents created as petrochemical and fuel products transition towards renewable resources. *International Journal of Molecular Sciences, 13*(6), 7134–7152. https://doi.org/10.3390/ijms13067134
- Constable, D. J. C., Curzons, A. D., Cunningham, V. L., & Hannah, R. E. (2007). Key green chemistry research areas—A perspective from pharmaceutical manufacturers. *Green Chemistry, 9*(5), 411–420. https://doi.org/10.1039/B703488C
- Dunn, P. J. (2012). The importance of green chemistry in process research and development. *Chemical Society Reviews, 41*(4), 1452–1461. https://doi.org/10.1039/C1CS15041C
- European Medicines Agency. (2023). *Guideline on the environmental risk assessment of medicinal products for human use*. EMA.
- FDA. (2019). *Advancement of emerging technology applications for pharmaceutical innovation and modernization*. U.S. Food and Drug Administration.
- Geissdoerfer, M., Savaget, P., Bocken, N. M. P., & Hultink, E. J. (2017). The circular economy—A new sustainability paradigm? *Journal of Cleaner Production, 143*, 757–768. https://doi.org/10.1016/j.jclepro.2016.12.048
- Innovative Medicines Initiative. (2021). *Sustainability and innovation in pharmaceutical manufacturing*. IMI.
- International Council for Harmonisation. (2009). *ICH Q8(R2): Pharmaceutical development*. ICH.
- International Council for Harmonisation. (2009). *ICH Q9: Quality risk management*. ICH.

- International Council for Harmonisation. (2009). *ICH Q10: Pharmaceutical quality system*. ICH.
- Jiménez-González, C., & Constable, D. J. C. (2011). *Green chemistry and engineering: A practical design approach*. Wiley.
- Jiménez-González, C., Poechlauer, P., Broxterman, Q. B., Yang, B. S., Am Ende, D., Baird, J., … Constable, D. J. C. (2011). Key green engineering research areas for sustainable manufacturing. *Organic Process Research & Development, 15*(4), 900–911. https://doi.org/10.1021/op200097d
- Kralisch, D., & Ott, D. (2011). Sustainable production concepts in the chemical industry: Process design and scale-up. *Chemical Engineering & Technology, 34*(12), 1911–1921. https://doi.org/10.1002/ceat.201100400
- Lee, J., Bagheri, B., & Kao, H. A. (2015). A cyber-physical systems architecture for Industry 4.0-based manufacturing systems. *Manufacturing Letters, 3*, 18–23. https://doi.org/10.1016/j.mfglet.2014.12.001
- Lipshutz, B. H., Ghorai, S., Cortes-Clerget, M., & Pahadi, N. K. (2018). The hydrophobic effect applied to organic synthesis: Recent advances. *Chemistry – A European Journal, 24*(26), 6672–6695. https://doi.org/10.1002/chem.201705067
- Mascia, S., Heider, P. L., Zhang, H., Lakerveld, R., Benyahia, B., Barton, P. I., … Jensen, K. F. (2013). End-to-end continuous manufacturing of pharmaceuticals: Integrated synthesis, purification, and formulation. *Angewandte Chemie International Edition, 52*(47), 12359–12363. https://doi.org/10.1002/anie.201305429
- McDonough, K., Baraldi, A., & Pammolli, F. (2021). Sustainability and innovation in pharmaceutical manufacturing. *Nature Sustainability, 4*(12), 1036–1044. https://doi.org/10.1038/s41893-021-00775-1
- NIIMBL. (2022). *Advancing biopharmaceutical manufacturing through public–private partnerships*. National Institute for Innovation in Manufacturing Biopharmaceuticals.
- Plutschack, M. B., Pieber, B., Gilmore, K., & Seeberger, P. H. (2017). The hitchhiker's guide to flow chemistry. *Chemical Reviews, 117*(18), 11796–11893. https://doi.org/10.1021/acs.chemrev.7b00183
- Rathore, A. S., & Winkle, H. (2009). Quality by design for biopharmaceuticals. *Nature Biotechnology, 27*(1), 26–34. https://doi.org/10.1038/nbt0109-26

- Rogers, A. J., & Ierapetritou, M. G. (2015). Challenges and opportunities in continuous pharmaceutical manufacturing. *Chemical Engineering Research and Design, 96*, 3–19. https://doi.org/10.1016/j.cherd.2014.10.003
- Roschangar, F., Sheldon, R. A., & Senanayake, C. H. (2015). Overcoming barriers to green chemistry in the pharmaceutical industry. *Green Chemistry, 17*(2), 752–768. https://doi.org/10.1039/C4GC01563K
- Segler, M. H. S., Preuss, M., & Waller, M. P. (2018). Planning chemical syntheses with deep neural networks and symbolic AI. *Nature, 555*(7698), 604–610. https://doi.org/10.1038/nature25978
- Schweidtmann, A. M., Mitsos, A., & Lapkin, A. A. (2021). Machine learning in chemical engineering: A perspective. *Chemical Engineering Journal, 421*, 127826. https://doi.org/10.1016/j.cej.2020.127826
- Sheldon, R. A. (2007). The E-factor: Fifteen years on. *Green Chemistry, 9*(12), 1273–1283. https://doi.org/10.1039/B713736M
- Sheldon, R. A. (2017). Metrics of green chemistry and sustainability. *ACS Sustainable Chemistry & Engineering, 6*(1), 32–48. https://doi.org/10.1021/acssuschemeng.7b03505
- Sherwood, J., Farmer, T. J., Clark, J. H., & Hunt, A. J. (2019). Towards a circular economy: Emerging trends in green chemistry. *Green Chemistry, 21*(9), 2164–2210. https://doi.org/10.1039/C8GC02498K
- Stahel, W. R. (2016). The circular economy. *Nature, 531*(7595), 435–438. https://doi.org/10.1038/531435a
- Woodcock, J., & Woosley, R. (2008). The FDA critical path initiative and its influence on new drug development. *Annual Review of Medicine, 59*, 1–12. https://doi.org/10.1146/annurev.med.59.090506.155819